Boeckh Michael
Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, School of Medicine, University of Washington, Seattle, WA, USA.
Br J Haematol. 2008 Nov;143(4):455-67. doi: 10.1111/j.1365-2141.2008.07295.x. Epub 2008 Sep 10.
Respiratory virus infections in hematopoietic cell transplant (HCT) recipients are a major cause of morbidity and mortality. While respiratory syncytial virus (RSV), human metapneumovirus, parainfluenzaviruses, and influenza viruses are well known for their potential to cause fatal pneumonia, information has only recently emerged regarding the significance of the newly discovered viruses, such as human coronaviruses NL63 and HKU1, and human bocavirus. Lymphopenia seems to be the most important risk factor for progression to lower respiratory tract disease. Airflow obstruction is another complication of respiratory virus infections after HCT, and data to date indicate this complication may occur following parainfluenza virus and RSV infection. Infection control procedures are key for prevention. Unfortunately, there are no randomized treatment studies, which make the interpretation of the literature on interventions difficult. This article reviews the spectrum of pathogens, epidemiology, risk factors and clinical manifestations of infection, as well as recent advances in diagnostic and clinical management.
造血细胞移植(HCT)受者的呼吸道病毒感染是发病和死亡的主要原因。虽然呼吸道合胞病毒(RSV)、人偏肺病毒、副流感病毒和流感病毒因其导致致命性肺炎的可能性而广为人知,但关于新发现病毒(如人冠状病毒NL63和HKU1以及人博卡病毒)的重要性的信息直到最近才出现。淋巴细胞减少似乎是进展为下呼吸道疾病的最重要危险因素。气流阻塞是HCT后呼吸道病毒感染的另一种并发症,迄今为止的数据表明,这种并发症可能在副流感病毒和RSV感染后发生。感染控制措施是预防的关键。不幸的是,目前尚无随机治疗研究,这使得对干预措施相关文献的解读变得困难。本文综述了病原体谱、流行病学、感染的危险因素和临床表现,以及诊断和临床管理方面的最新进展。